$ZYME

Zymeworks Inc. (ZYME) completed its acquisition of Theravance Biopharma, integrating the company to diversify its revenue streams. Zymeworks will host a conference call on September 28 to discuss the transaction details. The acquisition aims to advance Zymeworks' strategy of combining innovative R&D with commercial and royalty-based cash flows.

Zymeworks Inc. (ZYME) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Zymeworks Completes Acquisition of Theravance Biopharma • Conference call with Zymeworks management on September 28 at 8:30 am Eastern Time (ET) Vancouver, British Columbia (September 23, 2026) – Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portf

Zymeworks (ZYME) shares fell after management announced a shift to a hybrid royalty and acquisition strategy, raising concerns about execution risk and earnings timing. Despite optimism around its FDA-approved drug Ziihera, investors worry about near-term volatility. The company also announced a $125 million share repurchase program and a pending Theravance Biopharma deal, but these moves did not alleviate concerns. Long-term, Zymeworks' antibody platforms and cash position could support multipl

Analysts maintained Buy ratings on Zymeworks (ZYME), Axsome Therapeutics (AXSM), and Ocugen (OCGN). ZYME's PT is $38 (Citi) and $40.20 (consensus). AXSM's PT is $256 (Wells Fargo) and $291 (consensus). OCGN's PT is $12 (Noble Financial) and $10.13 (consensus). All have Strong Buy consensus.

Zymeworks (ZYME) presented at the Wells Fargo Healthcare Conference, highlighting its strategy focused on zanidatamab, royalty income, and acquisitions. Zanidatamab received FDA approval for gastric cancer, with Jazz Pharmaceuticals raising its peak sales estimate to $3B-$5B. Zymeworks raised $600M in debt, repurchased 10.5M shares, and plans to acquire Theravance Respiratory. Management expects profitability in 2026, with analysts forecasting 34% upside.

Zymeworks (ZYME) announced that its partner, Jazz Pharmaceuticals (JAZZ), received FDA approval for two Ziihera-containing regimens for treating HER2-positive gastroesophageal adenocarcinoma. This is the second FDA approval for zanidatamab in under two years, validating Zymeworks' Azymetric platform.

Citigroup maintained a Buy rating on Zymeworks (ZYME) and raised its price target to $38.00 from $37.00. The company's GF Value™ is $20.00, suggesting a 47.1% overvaluation. Zymeworks has a GF Score™ of 60, indicating moderate performance. The stock has strong momentum but weak profitability and growth metrics.

Zymeworks Inc (ZYME) shares rose 8% after FDA approval of Jazz Pharmaceuticals' Ziihera, triggering a $250M payment. ZYME's P/S ratio is 59.82x, higher than its historical median. Analysts set price targets at $55 and $40. The company's GF Score is 60, indicating moderate fundamental quality. Insiders sold $4.7M in shares over the past year.

H.C. Wainwright raised its price target on Zymeworks (ZYME) to $55 from $51, maintaining a Buy rating after FDA approval of Ziihera for HER2-positive gastroesophageal adenocarcinoma. The stock is up 85% over the past year. The approval triggers a $250 million payment from Jazz Pharmaceuticals (JAZZ). Analysts predict 188% revenue growth for FY2026. Zymeworks also announced an acquisition of Theravance Biopharma for $929 million.

Zymeworks (ZYME) shares rose 4% in pre-market trading ahead of an FDA decision on zanidatamab, a HER2-targeting antibody, with a PDUFA target date of August 25, 2026. Approval could trigger a $250 million milestone payment and up to $190 million more in other markets. Analysts have increased price targets ahead of the decision. The company is also pursuing a $929 million acquisition of Theravance Biopharma, expected to close in late 2026.